Foundation Medicine, QED Therapeutics to Develop CDx for Bile Duct Cancer

Dec 10, 2018

|

NEW YORK (GenomeWeb) – QED Therapeutics said today that it has partnered with Foundation Medicine to develop a companion diagnostic for its drug candidate infigratinib in patients with cholangiocarcinoma (bile duct cancer).

Infigratinib is an FGFR1-3-selective tyrosine kinase inhibitor, and the CDx will include the detection of activating FGFR2 fusions. It is expected to be incorporated into FoundationOne CDx, Foundation Medicine's FDA-approved comprehensive genomic profiling assay for all solid tumors, which includes several companion diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

A 'Double Whammy'

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

So Much Plastic

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

With a Little Lemon?

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

Science Has a Trio of Ruminant Genome Studies and More

In Science this week: three studies from the Ruminant Genome Project, and more.

Featured White Papers

Evaluation of the Oncomine BRCA Research Assay for Variant Detection by Next-Generation Sequencing

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Menu